Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Test of an Inhibitory Learning Model of Extinction in Treatment of Anxious Youth

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03372915
Recruitment Status : Completed
First Posted : December 14, 2017
Last Update Posted : December 17, 2020
Sponsor:
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
Recently, basic research conducted in adults has revealed that fear extinction, or the weakening of a learned fear response, may be best explained by principles of "inhibitory learning." New guidelines for the clinical practice of exposure therapy for anxiety disorders have arisen from research on inhibitory learning, but these guidelines have not yet been empirically tested in youth with anxiety disorders. The overall goal of this research is to investigate the acceptability, feasibility, and efficacy of conducting exposure therapy for anxiety disorders in youth according to clinical guidelines developed from basic research on inhibitory learning principles, using a pilot randomized controlled trial design.

Condition or disease Intervention/treatment Phase
Anxiety Disorders Behavioral: Standard Exposure Behavioral: Exposure + Inhibitory Learning Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Testing an Inhibitory Learning Model of Extinction in Exposure-Based Anxiety Treatment for Youth: Feasibility, Acceptability, and Efficacy
Actual Study Start Date : January 31, 2018
Actual Primary Completion Date : December 1, 2020
Actual Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Arm Intervention/treatment
Active Comparator: Standard Exposure
This arm will receive exposure therapy conducted according to standard care practices.
Behavioral: Standard Exposure
Exposure therapy conducted according to standard clinical care practices

Experimental: Exposure + Inhibitory Learning
This arm will receive exposure therapy conducted according to principles of inhibitory learning.
Behavioral: Exposure + Inhibitory Learning
Exposure therapy conducted according to practice recommendations based derived from research on inhibitory learning theories of fear extinction




Primary Outcome Measures :
  1. Change in Percentage of Exposure Refusals (Feasibility Measure) [ Time Frame: Treatment weeks 5, 6, 7, and 8 ]
    Therapists will record the percentage of exposures the patient refused to complete during the session.

  2. Change in Latency to Initiating Exposure (Feasibility Measure) [ Time Frame: Treatment weeks 5, 6, 7, 8 ]
    Therapist will record the average amount of time the patient delayed before initiating each exposure in session

  3. Early Treatment Termination (Feasibility Measure) [ Time Frame: Measure will be collected following the patient's termination from treatment ]
    Information will be collected regarding whether the patient terminated treatment early (before session 9)

  4. Change in Homework Completion (Feasibility Measure) [ Time Frame: Treatment weeks 6, 7, 8, and 9 ]
    Therapist will record the number of exposure sessions for which the patient completed homework

  5. Client Satisfaction Questionnaire-8 (CSQ-8) [ Time Frame: Week 9 (End of Treatment) ]
    8-item measure of patient satisfaction with treatment. The measure is rated on a four-point scale, with possible scores ranging from 8-32.


Secondary Outcome Measures :
  1. Change in Distress Tolerance Scale--Child (DTS-C) [ Time Frame: Treatment Week 1, Week 5, and Week 9 (End of Treatment) ]
    A 15-item self-report measure of difficulties managing distress and related emotions. The measure is rated on a 5-point scale, with possible scores ranging from 15 to 65. Higher scores indicate greater ability to tolerate distress.

  2. Change in Child Avoidance Measure, Self and Parent Report (CAMS/P) [ Time Frame: Treatment Week 1, Week 5, and Week 9 (End of Treatment) ]
    The CAMS/P are 8-item child- and parent-report (respectively) measures of behavioral avoidance. The measure is rated on a 4-point scale, with possible scores ranging from 0 to 24. Higher scores indicate greater behavioral avoidance.

  3. Change in Avoidance and Fusion Questionnaire--Youth (AFQ-Y) [ Time Frame: Treatment Week 1, Week 5, and Week 9 (End of Treatment) ]
    A 17-item self-report measure of experiential avoidance and cognitive fusion. The measure is rated on a 4-point scale, with possible scores ranging from 0 to 68. Higher scores indicate greater cognitive fusion and experiential avoidance.

  4. Change in Parent Acceptance and Action Questionnaire (PAAQ) [ Time Frame: Treatment Week 1, Week 5, and Week 9 (End of Treatment) ]
    A 15-item measure of parent experiential avoidance, or parental actions intended to control the form and frequency of their child's emotional experiences. Items are rated on a 7-point scale, with possible scores ranging from 17 to 105. Higher scores indicate less parental experiential avoidance and less effort to control child emotional experiences.

  5. Change in Screen for Child Anxiety Related Disorders (SCARED), Self and Parent Report [ Time Frame: Treatment Week 1, Week 5, Week 6, Week 7, Week 8, and Week 9 (End of Treatment) ]
    A 41-item child- and parent-report measure assessing symptoms of anxiety in youth ages 7 to 19. Items are rated on a 3-point scale, with scores ranging from 0 to 82. Higher scores indicate greater anxiety symptoms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Primary or secondary diagnosis of an anxiety disorder
  2. Ability of both child and caregiver to read and understand English
  3. Ability of child and at least one caregiver to attend weekly sessions

Exclusion Criteria:

  1. Diagnosis of autism spectrum disorder, intellectual development disorder, or limited cognitive functioning (i.e., documented Intelligence Quotient [IQ]<80).
  2. Diagnosis of a psychotic disorder or bipolar disorder
  3. Severe and current suicidal ideation, history of suicide attempt in past six months, or frequent and persistent self-injurious behavior
  4. Diagnosis of a substance use disorder or significant, recent substance use
  5. Any youth receiving concurrent individual therapy will also be excluded from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03372915


Locations
Layout table for location information
United States, Colorado
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
Investigators
Layout table for investigator information
Principal Investigator: Jessica Hawks, PhD University of Colorado, Denver
Publications:
Arch, J. J., & Abramowitz, J. S. (2015). Exposure therapy for obsessive-compulsive disorder: An optimizing inhibitory learning approach. Journal of Obsessive-Compulsive and Related Disorders, 6, 174-182.
Ehrenreich-May, J., Kennedy, S. M., Sherman, J., Bilek, E. L., Buzzella, B., Bennett, S., & Barlow, D. H. (In press). Unified protocols for transdiagnostic treatment of emotional disorders in children and adolescents. New York: Oxford University Press.
Muris, P., Merckelbach, H., van Brakel, A., Mayer, B., & van Dongen, L. (1998). The Screen for Child Anxiety Related Emotional Disorders (SCARED): Relationship with anxiety and depression in normal children. Personality and Individual Differences, 24(4), 451-456.
Simons, J. S., & Gaher, R. M. (2005). The Distress Tolerance Scale: Development and validation of a self-report measure. Motivation and Emotion, 29(2), 83-102.

Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT03372915    
Other Study ID Numbers: 17-2040
First Posted: December 14, 2017    Key Record Dates
Last Update Posted: December 17, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anxiety Disorders
Mental Disorders